美常安联合六味安消治疗功能性便秘的临床研究  

A Clinical Controlled Study of Medilac-S and Liuwei-Anxiao Capsules in Patients with Functional Constipation.

作　　者：唐彤宇[1] 秦俊杰[1] 王英凯[1] 高普均[1] 朴云峰[1] 

机构地区：[1]吉林大学第一医院消化科,130021

出　　处：《中国医药指南》2009年第4期20-21,共2页Guide of China Medicine

摘　　要：目的探讨微生态制剂美常安与六味安消联合治疗功能性便秘的临床疗效及安全性。方法采用随机对照研究,将65例功能性便秘患者分为2组:A组为治疗组,共33例。予六味安消3粒/次,3次/d,美常安500mg/次,3次/d,口服;B组为对照组,32例。予六味安消3粒/次,3次/d,口服。疗程4周。观察治疗前后排便次数、大便性状、排便困难症状评分的变化。结果治疗组中上述指标较对照组改善显著。结论美常安联合六味安消治疗能明显增加便秘患者排便次数并改善大便性状,缓解排便困难症状,安全性好。Objective To evaluate the efficacy and safety of Medilac-s and Liuwei-Anxiao capsules in patients with functional constipation. Methods Sixty patients diagnosed as functional constipation according to the Rome Ⅲ criteria were randomly divided into two groups and followed up for 4 weeks. A group （n=33）was given with 3 capsules of liuwei-anxiao and medilac-s 500mg, three times daily and B group（n=32） was given with 3 capsules liuwei-anxiao and medilac-s 500mg, three times daily. The bowel movement frequencies, stool property and constipation symptom scores were observed. Results Four weeks later, The bowel movement frequencies,the Bristol Stool Form Scale, the symptomatic scores have significant improvement in both groups compared with baseline. There was significant difference of efficiency in therapy group than that in control group （P〈0.05）. Conclusion Medilac-s and Liuwei-Anxiao capsules are effective and safe for patients with chronic functional constipation. Combined with Bacillus subtilis and Enterococcus faecim could improve patients stool description, clinical symptom..

关 键 词：功能性便秘 美常安 六味安消 药物疗法 

分 类 号：R975[医药卫生—药品]